DAPB, a new molecule including danshensu, borneol, and a mother nucleus of ACEI (Angiotensin-converting enzyme inhibitors), is being developed as an antihypertensive candidate compound. A rapid, accurate, and sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was established and validated for the determination of DAPB in rat plasma. Chromatographic separation was performed on an Agilent SB-C18 column after protein precipitation by acetonitrile with a mobile phase consisting of acetonitrile and deionized water with 0.02% formic acid and 5 mM NH 4 F ( v / v ) at a flow rate of 0.2 mL/min. Quantification was performed using electrospray positive ionization mass spectrometry in the multiple reaction monitoring (MRM) mode. The method was linear over the range of 2-1000 ng/mL. The intra- and inter-day precision was within 12%, with accuracies less than 7%. Stability was within the acceptable limits under various storage and processing conditions. No apparent matrix effect was detected. The validated method was applied to the pre-clinical pharmacokinetic study of DAPB after oral administration of 30 mg/kg and intravenous administration of 6 mg/kg in rats.
Keyphrases
- liquid chromatography tandem mass spectrometry
- simultaneous determination
- liquid chromatography
- solid phase extraction
- mass spectrometry
- tandem mass spectrometry
- high performance liquid chromatography
- high resolution mass spectrometry
- gas chromatography
- ultra high performance liquid chromatography
- high resolution
- ms ms
- angiotensin converting enzyme
- molecularly imprinted
- angiotensin ii
- capillary electrophoresis
- blood pressure
- magnetic resonance imaging
- magnetic resonance
- room temperature
- ionic liquid
- binding protein
- neural network
- loop mediated isothermal amplification